Latest Breaking News On - Integrated summary - Page 1 : comparemela.com

Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, have announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity. The company reported that with this approval, INJECTAFER is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.

United statesRavi tayiAmerican heart associationDaiichi sankyo groupDaiichi sankyo incEuropean unionPharmaceuticals incAdverse drug events to american regent incYork heart associationAmerican regent incYork heart association functional classificationPharmacosmos therapeutics incDrug administrationLuitpold pharmaceuticals incDaiichi sankyoAmerican regent